Claims
- 1. A compound of formula (I): or a salt thereof, or a solvate thereof, characterised in that:Ar represents substituted or unsubstituted aryl, wherein the optional substituents are selected from alkyl, hydroxy or alkoxy or, if attached to adjacent carbon atoms any two substituents together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five to six atoms wherein one, two or three of the said atoms are oxygen or nitrogen; A represents a C1-4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C1-6 alkyl groups; R1 represents hydrogen, alkyl, alkenyl or cycloalkyl; one or two of of the group of R2, R3 and R4 represents nitro the remaining members of the group of R2, R3 and R4 represent hydrogen; X represents a —CO—NH— moiety; and Z represents C2-4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C1-6 alkyl groups.
- 2. A compound according to claim 1, wherein Ar represents a substituted or unsubstituted phenyl group.
- 3. A compound according to claim 1, wherein Ar represents a phenyl group substituted with 1 or 2 alkoxy groups.
- 4. A compound according to claim 1, wherein R1 represents hydrogen, C2-6 alkyl, alkenyl or cycloalkyl.
- 5. A compound according to claim 1, wherein R1 is hydrogen.
- 6. A compound according to claim 1, wherein one of R2, R3 and R4 represents nitro and the remaining members of the group of R2, R3 and R4 represent hydrogen.
- 7. A compound according to claim 6, wherein R2 represents 4-nitro and R3 and R4 each represents hydrogen.
- 8. A compound according to claim 1, wherein Z represents CH2CH2CH2.
- 9. A compound which is N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride.
- 10. A process for preparing a compound of formula (I) as defined in claim 1, or a salt thereof, or a solvate thereof, which process comprises:(i) reacting a compound of formula (II): wherein A, Ar, R1 and Z are as defined in relation to formula (I), with a compound of formula (III): wherein R2, R3 and R4 are as defined in relation to formula (I) and L1 represents a leaving group; or (ii) demethylating a compound of formula (VII): wherein A, Ar, R2, R3, R4, X and Z are as defined in relation to the compounds of formula (I); and thereafter, as required, converting any —NH— moiety so formed into a group NR5 wherein R5 represents C2-6 alkyl, an alkenyl or a cycloalkyl group; or (iii) reacting a compound of formula (VIII): wherein R2, R3 R4 X and Z are as defined in relation to formula (I) and L3 is a leaving group, such as a halogen, with a compound of formula (IX): wherein A, Ar, R1 are as defined in relation to formula (I); and thereafter carrying out one or more of the following optional steps:(i) converting a compound of formula (I) into a further compound of formula (I); (ii) preparing a salt of the compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.
- 11. A pharmaceutical composition comprising a compound of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier.
- 12. A method for the treatment and/or prophylaxis of arrhythmia and ischaemic rhythm disorders in a human or non-human mammal which comprises administering an effective, non-toxic amount of a compound of the general formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a human or non-human manual in need thereof.
- 13. A compound which is N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-4-nitro benzamide; or a salt thereof, or a solvate thereof.
- 14. The compound according to claim 13 which is N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-4-nitro benzamide hydrochloride.
Priority Claims (1)
Number |
Date |
Country |
Kind |
94 12806 |
Oct 1994 |
FR |
|
Parent Case Info
This is a continuation of application Ser. No.: 09/825,187 filed Apr. 2, 2001, now abandoned, which is a continuation of 09/384,600 filed Aug. 27, 1999 now abandoned, which is a divisional of application Ser. No. 08/836,019 filed Apr. 25, 1997, now U.S. Pat. No. 54,771,793 which is a 371 of International Application No. PCT/EP95/04203 filed Oct. 24, 1995, which claims priority to 94/12806 filed Oct. 26, 1994.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5208252 |
Russell et al. |
May 1993 |
A |
5977179 |
Nadler et al. |
Nov 1999 |
A |
Foreign Referenced Citations (2)
Number |
Date |
Country |
A32 42 344 |
May 1984 |
DE |
A0 285 284 |
Oct 1988 |
EP |
Non-Patent Literature Citations (1)
Entry |
Biochem J., Sim, et al. “Metabolites of procainamide and practolol inhibit complement components C3 and C4”. p. 324. |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09/825187 |
Apr 2001 |
US |
Child |
10/060760 |
|
US |
Parent |
09/384600 |
Aug 1999 |
US |
Child |
09/825187 |
|
US |